Skip to content

Interim report January-September 2022: FIRST QUARTER WITH SALES ABOVE SEK 200 MILLION

THIRD QUARTER 2022 (JUL – SEP)

Net sales amounted to SEK 205.1 million (95.3), corresponding to an increase of 115 percent compared with the corresponding period in the preceding year.

For comparable units, sales increased by 39 percent.

Operating profit amounted to SEK 42.7 million (7.6).

Net profit amounted to SEK 28.5 million (14.4), corresponding to earnings per share of SEK 0.56 (0.33).

Cash flow from operating activities amounted to an inflow of SEK 9.5 million (51.6). As of September 30, 2022, cash and cash equivalents amounted to SEK 370.1 million (310.6).

FIRST NINE MONTHS OF 2022 (JAN–SEP)

Net sales amounted to SEK 552.4 million (169.1), corresponding to an increase of 227 percent compared with the corresponding period in the preceding year.

For comparable units, sales increased by 39 percent.

Operating profit amounted to SEK 101.3 million (12.0).

Net profit amounted to SEK 71.5 million (19.4), corresponding to earnings per share of SEK 1.41 (0.49).

Cash flow from operating activities amounted to an inflow of SEK 50.9 million (52.1).

Gothenburg, Sweden, November 10, 2022
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

Skip to navigation